Ionis Pharmaceuticals (MEX:IONS) Change In Receivables : MXN-233 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Change In Receivables?

Ionis Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2024 was MXN-1,549 Mil. It means Ionis Pharmaceuticals's Accounts Receivable increased by MXN1,549 Mil from Sep. 2024 to Dec. 2024 .

Ionis Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2024 was MXN117 Mil. It means Ionis Pharmaceuticals's Accounts Receivable declined by MXN117 Mil from Dec. 2023 to Dec. 2024 .

Ionis Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2024 was MXN0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ionis Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ionis Pharmaceuticals's liquidation value for the three months ended in Dec. 2024 was MXN-2,324 Mil.

Ionis Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Ionis Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Change In Receivables Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-261.98

293.51

708.84

-1,223.15

116.58

Ionis Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															759.68	1,537.44	-405.22	183.73	-1,548.74

Ionis Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-233 Mil.

Ionis Pharmaceuticals (MEX:IONS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ionis Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	4725.401	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Ionis Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Ionis Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	47919.224	-	50373.273	+	0.75 * 0	+	0.5 * 260.947
=	-2,324

Ionis Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

IONS:USA 0JDI:UK ISI:Germany ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.